Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
102.84
-0.08 (-0.08%)
At close: Sep 8, 2026, 4:00 PM EDT
102.00
-0.92 (-0.89%)
After-hours: Sep 8, 2026, 7:59 PM EDT
Haemonetics Revenue
Haemonetics had revenue of $339.38M in the quarter ending June 27, 2026, with 5.60% growth. This brings the company's revenue in the last twelve months to $1.35B, up 0.44% year-over-year. In the fiscal year ending March 28, 2026, Haemonetics had annual revenue of $1.33B, down -1.97%.
Revenue (ttm)
$1.35B
Revenue Growth
+0.44%
P/S Ratio
3.46
Revenue / Employee
$449,323
Employees
3,009
Market Cap
4.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 28, 2026 | 1.33B | -26.80M | -1.97% |
| Mar 29, 2025 | 1.36B | 51.77M | 3.95% |
| Mar 30, 2024 | 1.31B | 140.40M | 12.01% |
| Apr 1, 2023 | 1.17B | 175.46M | 17.67% |
| Apr 2, 2022 | 993.20M | 122.73M | 14.10% |
| Apr 3, 2021 | 870.46M | -118.02M | -11.94% |
| Mar 28, 2020 | 988.48M | 20.90M | 2.16% |
| Mar 30, 2019 | 967.58M | 63.66M | 7.04% |
| Mar 31, 2018 | 903.92M | 17.81M | 2.01% |
| Apr 1, 2017 | 886.12M | -22.72M | -2.50% |
| Apr 2, 2016 | 908.83M | -1.54M | -0.17% |
| Mar 28, 2015 | 910.37M | -28.14M | -3.00% |
| Mar 29, 2014 | 938.51M | 46.52M | 5.22% |
| Mar 30, 2013 | 891.99M | 164.15M | 22.55% |
| Mar 31, 2012 | 727.84M | 51.15M | 7.56% |
| Apr 2, 2011 | 676.69M | 31.26M | 4.84% |
| Apr 3, 2010 | 645.43M | 47.55M | 7.95% |
| Mar 28, 2009 | 597.88M | 81.44M | 15.77% |
| Mar 29, 2008 | 516.44M | 66.83M | 14.86% |
| Mar 31, 2007 | 449.61M | 29.87M | 7.12% |
| Apr 2, 2006 | 419.73M | 36.14M | 9.42% |
| Apr 2, 2005 | 383.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.50B |
| Insulet | 3.05B |
| Integer Holdings | 1.84B |
| LivaNova | 1.47B |
| Neogen | 870.40M |
| iRhythm Holdings | 825.34M |
| TransMedics Group | 668.47M |
| UFP Technologies | 631.64M |
HAE News
- 5 days ago - Haemonetics price target raised to $125 from $105 at Raymond James - TheFly
- 18 days ago - Haemonetics price target raised to $119 from $96 at Baird - TheFly
- 20 days ago - Haemonetics price target raised to $118 from $95 at Barrington - TheFly
- 21 days ago - Haemonetics rises 16.2% - TheFly
- 21 days ago - Haemonetics rises 15.2% - TheFly
- 21 days ago - Haemonetics announces supply agreement with CSL Plasma - TheFly
- 21 days ago - Haemonetics up 9% at $98.50 in pre-market on CSL Plasma supply agreement - TheFly
- 21 days ago - Haemonetics price target raised to $120 from $100 at BofA - TheFly